Drug intelligence / Profile preview

MY002

Development stage: Preclinical
Lead developer: Monyan Pharmaceutical

Overview

MY002 is a Traditional Chinese Medicine (TCM) candidate classified as a Class 1.1 new drug, currently under development by Monyan Pharmaceutical. It is being investigated for the treatment of male reproductive health conditions, specifically oligospermia (low sperm count) and asthenospermia (reduced sperm motility). As a Class 1.1 TCM, MY002 is a novel therapeutic entity that has not been previously marketed in China. The program is currently in the IND-enabling phase, with an Investigational New Drug (IND) application projected for 2027.

Beyond the preview

Go deeper on MY002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MY002.

Explore the full profile